The von willebrand disease treatment market size is predicted to reach US$ 905 million by 2030 from US$ 502.88 million in 2021, expanding growth at a CAGR of 6.1% from 2021 to 2030.
The von willebrand disease treatment market size is predicted to reach US$ 905 million by 2030 from US$ 502.88 million in 2021, expanding growth at a CAGR of 6.1% from 2021 to 2030.
The global von Willebrand disease treatment market has expanded significantly in the last decade due to rise in the number of patient assistance programs and promising drug pipeline & approvals.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38195
Von Willebrand disease is an inherited bleeding disorder caused due to deficiency or dysfunction of von Willebrand factor (VWF). Moreover, genetic mutation is one of the causes of von Willebrand disease. Defects or deficiency of VWF can cause bleeding by impairing platelet adhesion or by reducing the concentration of FVIII. Various treatment options are available for the treatment of von Willebrand disease, including desmopressin, clot-stabilizing medications, replacement therapies, and contraceptives. The expansion of the global von Willebrand disease treatment market can be ascribed to an increase in number of patient assistance programs and the demand for recombinant therapies.
The von Willebrand disease treatment market growth is largely driven by factors, including increasing collaborations and partnerships between top-tier research institutes and regulatory bodies, entry of new von Willebrand disease therapies, and growing awareness related to von Willebrand disease due to a surge in the number of government initiatives and awareness programs. While research and development activities are set to play an imperative role in the expansion of the von Willebrand disease treatment market, other factors that are likely to influence the market growth include rise in demand for recombinant therapies and strong product pipeline.
Market Growth to Remain Steady amid COVID-19 Pandemic
The ongoing COVID-19 pandemic is expected to have a short-term impact on the overall growth of the global von Willebrand disease treatment market. Although the sales of medication and adoption of various therapies could see a slight dip due to the COVID-19 situation, research and development activities are expected to continue in full swing across the von Willebrand disease treatment market. Several research institutes around the world are increasingly assessing the relationship between von Willebrand disease and COVID-19 due to which, new areas pertaining to von Willebrand disease treatment are being explored. While drug development and research activities are likely to remain unaffected, the number of clinical tests and procedures could potentially witness a slight dip in 2020.
Advent of New Therapies for von Willebrand Disease Likely to Boost Market Growth
Research and development activities are set to play an important role in augmenting the growth of the global von Willebrand disease treatment market during the assessment period. The entry of new therapies and von Willebrand disease treatment, as a result of research programs and initiatives, is expected to provide a considerable boost to the global von Willebrand disease treatment market. Majorly, the management of von Willebrand disease is mainly based on the dual correction of primary hemostasis defect caused due to inherited deficiency of von Willebrand factor (VWF) and the secondary defect factor VIII coagulant activity. At present, new therapies are aimed toward addressing primary deficiency in the von Willebrand disease. Considerable research is being carried out to evaluate the efficacy of new products in different clinical situations. In addition, scientists and researchers are also focusing on testing the efficacy of new therapies and products in unexplored situations, including long-term use of prophylaxis, use in children, and during recurrent gastrointestinal bleeding.
Key Market Trends
Replacement Therapy Segment Expected to Register Significant Growth Over the Forecast Period
The replacement therapy segment is anticipated to witness significant growth. Replacement therapy is referred to as the therapy involving the supply of a substance (such as a hormone or nutrient) lacking in or lost from the body. The major factors fueling the segment’s growth are the number of people with Von Willebrand disease and the increasing number of product approvals.
As per the Annual Global Survey by the World Hemophilia Federation, in 2020, the total number of people identified with the Von Willebrand disease globally was 84,197. In addition, several market players are engaged in obtaining approvals for replacement therapies for the treatment of the Von Willebrand disease. For instance, in June 2021, Takeda Pharmaceutical Company Limited reported that the United States Food and Drug Administration (FDA) had accepted the supplemental Biologics License Application (sBLA) for VONVENDI [von Willebrand factor (Recombinant)] for review. This is meant for prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults (aged 18 years and older) with von Willebrand disease.
Thus, due to the above-mentioned factors, the segment is expected to witness significant growth over the forecast period.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38195
Report Highlights
- Based on disease type, the type 1 von Willebrand disease segment dominated the global von Willebrand disease treatment market in 2020. This trend is projected to continue during the forecast period. The rise in the number of VWD cases, technological advancements, and new product launches contributed to the significant share held by the segment in 2020. Moreover, increase in patient pool for type 1 disease-Type 1 VWD accounts for 60% to 80% of the patients with VWD-is likely to drive the segment.
- The type 2 von Willebrand disease segment was followed by the type 1 von Willebrand disease segment, in terms of market share, in 2020. Increasing patient pool for different type 2 VWD, i.e. type 2A, type 2B, type 2M, and type 2N, is likely to drive the segment.
- In terms of drug, the desmopressin segment accounted for a prominent share of the global von Willebrand disease treatment market in 2020, owing to high effectiveness in the treatment of the disease. Desmopressin is first line of treatment for von Willebrand disease. Increasing use of desmopressin in the treatment of VWD is likely to drive the segment.
- In terms of route of administration, the injection segment dominated the global von Willebrand disease treatment market, in terms of revenue, in 2020. The trend is expected to continue during the forecast period. Factors such as easy, convenient route of administration of drugs, and availability of most treatment products in injection form are likely to drive the injection segment.
- In terms of gender, the women segment dominated the global von Willebrand disease treatment market, in terms of revenue, in 2020. Increasing incidence of bleeding disorders such as VWD and menorrhagia in women is likely to fuel the segment.
- In terms of distribution channel, the hospital pharmacies segment led the global von Willebrand disease treatment market in terms of revenue in 2020. The trend is expected to continue during the forecast period. Rapid increase in the number of hospitals and a wide range of services available in multispecialty hospitals are likely to boost the segment during the forecast period. The retail pharmacies segment is witnessing expansion, as medicines for von Willebrand disorders are advised for longer period, which prompts patients to prefer retail stores instead of a visit to the hospitals.
- In terms of region, the North America dominated the global von Willebrand disease treatment market in 2020. It was followed by Europe. Significant share held by North America can be ascribed to the presence of players with significant research and development activities in order to develop new products for the treatment VWD. Moreover, a rise in prevalence of VWD is anticipated to fuel the von Willebrand diseases treatment market in the region. According to the National Hemophilia Foundation, around 1% of the U.S. population suffers from VWD.
- The von Willebrand disease treatment market in Asia Pacific is anticipated to expand at a rapid pace from 2021 to 2030. The increase in opportunities to launch new products and a surge in the demand for new treatment options are key factors that are expected to boost the von Willebrand disease treatment market in Asia Pacific.
Competitive Landscape
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.
The analysts have provided a comprehensive analysis of the competitive landscape of the global von willebrand disease treatment market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.
- Company Overview
- Company Market Share/Positioning Analysis
- Product Offerings
- Financial Performance
- Recent Initiatives
- Key Strategies Adopted by Players
- Vendor Landscape
- List of Suppliers
- List of Buyers
Key players operating in the global market include Octapharma AG, Grifols, S.A., Shire plc, Bayer AG, CSL Behring, Pfizer, Inc., Akorn, Inc., and Ferring B.V.
Market Segmentation
By Disease Type
-
- Type 1 von Willebrand Disease
- Type 2 von Willebrand Disease
- Type 3 von Willebrand Disease
- Acquired von Willebrand Disease
By Drug
-
- Desmopressin
- Clot-stabilizing Medications
- Replacement Therapies
- Contraceptives
- Others
By Route of Administration
-
- 8Oral
- Injection
- Others
By Gender
-
- Men
- Women
By Distribution Channel
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
-
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38195
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/